Molekyylikemian

Molekyylikemian is an Estonian biotechnology firm established in 2010 in Tallinn. The company concentrates on developing small‑molecule drugs for metabolic disorders. It specializes in synthetic organic chemistry, high‑throughput screening, and structure‑activity relationship studies. Its flagship pipeline agent is MK‑123, an orally bioavailable inhibitor targeting monoamine oxidase B, which is currently in phase II clinical trials. The company collaborates with the University of Tartu’s Department of Organic Chemistry and the Estonian Research Council.

Molekyylikemian employs approximately 70 scientists, including chemists, pharmacologists, and computational modelers. The corporate headquarters features a 15,000‑square‑meter research laboratory with automated synthesis modules, and a strategic investment from the European Innovation Fund in 2015 enabled the relocation of its production facility to a GMP‑compliant plant in Narva. Current research focuses include drug design for neurodegenerative diseases, rare metabolic syndromes, and antimicrobial agents. The firm publishes in leading peer‑reviewed journals and participates in international conferences such as the International Conference on Molecular Sieving and Drug Design. Its corporate philosophy emphasizes sustainable chemistry and open data sharing.

Molekyylikemian has been recognized by the Estonian Ministry of Economic Affairs as a key innovator in the life‑sciences sector. The company’s mission statement reads: “To accelerate the translation of molecular insights into safe, effective therapeutics that improve human health.” Future plans involve expanding into biologics and engaging in joint ventures with other European biotech groups.